William Blair Analysts Reduce Earnings Estimates for Envista

Envista Holdings Co. (NYSE:NVST - Free Report) - William Blair reduced their Q1 2025 EPS estimates for Envista in a research report issued to clients and investors on Thursday, February 6th. William Blair analyst B. Vazquez now anticipates that the company will earn $0.21 per share for the quarter, down from their previous estimate of $0.27. The consensus estimate for Envista's current full-year earnings is $1.06 per share. William Blair also issued estimates for Envista's Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.21 EPS, FY2025 earnings at $0.97 EPS and FY2026 earnings at $1.06 EPS.

Other analysts have also issued research reports about the stock. Needham & Company LLC restated a "hold" rating on shares of Envista in a research report on Thursday, February 6th. Morgan Stanley increased their price objective on shares of Envista from $19.00 to $20.00 and gave the stock an "equal weight" rating in a report on Thursday, February 6th. Stifel Nicolaus boosted their target price on shares of Envista from $18.00 to $21.00 and gave the company a "buy" rating in a report on Wednesday, October 23rd. Robert W. Baird increased their price target on shares of Envista from $17.00 to $22.00 and gave the stock a "neutral" rating in a research note on Thursday, October 31st. Finally, Mizuho assumed coverage on shares of Envista in a research note on Wednesday, December 4th. They set an "underperform" rating and a $20.00 price objective for the company. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $20.21.

Envista Price Performance

Shares of NYSE:NVST traded up $0.63 during midday trading on Monday, hitting $21.49. 1,992,297 shares of the stock were exchanged, compared to its average volume of 2,225,396. The stock has a market cap of $3.70 billion, a P/E ratio of -3.31, a PEG ratio of 2.06 and a beta of 1.34. Envista has a twelve month low of $15.15 and a twelve month high of $23.06. The company has a 50 day moving average price of $19.90 and a 200-day moving average price of $19.28. The company has a current ratio of 2.04, a quick ratio of 1.77 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Franklin Resources Inc. raised its position in shares of Envista by 72.6% in the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company's stock valued at $132,223,000 after purchasing an additional 2,882,844 shares in the last quarter. Iron Triangle Partners LP bought a new stake in shares of Envista in the third quarter worth $43,262,000. Norges Bank bought a new position in Envista during the 4th quarter valued at $38,052,000. Point72 Asset Management L.P. acquired a new position in Envista during the 3rd quarter worth $37,559,000. Finally, Polar Asset Management Partners Inc. increased its position in shares of Envista by 375.6% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company's stock worth $29,586,000 after purchasing an additional 1,182,450 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.